Drug Approval | January 08, 2026
Rapid-acting ADHD treatment Azstarys now approved in China
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Heart failure affects an estimated 64.3 million people worldwide
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Subscribe To Our Newsletter & Stay Updated
